Dr Silke Schwengberg
Silke holds a PhD in cell biology and immunology from the University of Hannover, Germany, and has over 20 years of experience in stem cell-based models for drug discovery. She is passionate about developing and applying functional iPSC cardiomyocyte assays to assess the efficacy and safety of novel drug therapies.
Before joining Ncardia, Silke led cross-functional teams at stem-cell technology companies and worked as an independent scientific consultant for eight years, providing expertise in assay development for drug discovery and toxicology.
At Ncardia, Silke applies her extensive experience to advance innovative toxicology solutions, supporting the development of safer and more effective therapeutics.
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.